NRP1 and neoplasm: Moreover, CD8+ TIL from mice treated anti-Nrp-1 i.p. plus anti-PD-1 combination or anti-Nrp-1 i.t. plus anti-PD-1 combination kill more efficiently MC-38 tumour cells ex vivo than TIL from mice treated with anti-Nrp-1 i.t. or i.p. alone, anti-PD-1 alone or isotype control mAb (Fig. 6i).